Photocure ASA
OSE:PHO

Watchlist Manager
Photocure ASA Logo
Photocure ASA
OSE:PHO
Watchlist
Price: 57.8 NOK 0.87%
Market Cap: 1.6B NOK

Relative Value

The Relative Value of one PHO stock under the Base Case scenario is 75.12 NOK. Compared to the current market price of 57.8 NOK, Photocure ASA is Undervalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PHO Relative Value
Base Case
75.12 NOK
Undervaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
80
vs Industry
39
Median 3Y
3.3
Median 5Y
6.5
Industry
2.4
Forward
2.7
vs History
vs Industry
1
Median 3Y
-32.3
Median 5Y
53.7
Industry
20.5
Forward
42.9
vs History
82
vs Industry
22
Median 3Y
29.8
Median 5Y
49
Industry
15.4
vs History
11
vs Industry
8
Median 3Y
-37.5
Median 5Y
-29.6
Industry
22.6
vs History
76
vs Industry
24
Median 3Y
3.3
Median 5Y
5
Industry
2
vs History
85
vs Industry
44
Median 3Y
2.7
Median 5Y
5.7
Industry
2.5
Forward
2.2
vs History
84
vs Industry
64
Median 3Y
2.9
Median 5Y
6.1
Industry
4.9
vs History
47
vs Industry
15
Median 3Y
18
Median 5Y
25
Industry
12.6
Forward
15.6
vs History
17
vs Industry
6
Median 3Y
-39.9
Median 5Y
26.2
Industry
15.6
Forward
24.8
vs History
82
vs Industry
27
Median 3Y
24.1
Median 5Y
40.3
Industry
13.9
vs History
63
vs Industry
23
Median 3Y
30
Median 5Y
29.3
Industry
17.7
vs History
73
vs Industry
25
Median 3Y
3.2
Median 5Y
5.4
Industry
1.8

Multiples Across Competitors

PHO Competitors Multiples
Photocure ASA Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Photocure ASA
OSE:PHO
1.6B NOK 3 -323.5 25.6 61.7
US
Eli Lilly and Co
NYSE:LLY
783.4B USD 17.4 74 43 47.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
389.2B USD 4.4 27.7 13 17
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 7.5 21.6 14.2 16.2
CH
Roche Holding AG
SIX:ROG
233.4B CHF 4 20.3 11.3 13.4
UK
AstraZeneca PLC
LSE:AZN
173.2B GBP 4.1 31.7 126.6 193.4
US
Merck & Co Inc
NYSE:MRK
223.1B USD 3.5 13 8.8 10.4
CH
Novartis AG
SIX:NOVN
196.7B CHF 4.3 18.6 11.3 14.4
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
142.8B USD 2.2 17.8 8.5 12.1
P/E Multiple
Earnings Growth PEG
NO
Photocure ASA
OSE:PHO
Average P/E: 28.1
Negative Multiple: -323.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
74
48%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.7
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
21.6
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.3
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
31.7
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13
17%
0.8
CH
Novartis AG
SIX:NOVN
18.6
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.8
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
Photocure ASA
OSE:PHO
Average EV/EBITDA: 397.8
25.6
53%
0.5
US
Eli Lilly and Co
NYSE:LLY
43
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.6
9%
14.1
US
Merck & Co Inc
NYSE:MRK
8.8
9%
1
CH
Novartis AG
SIX:NOVN
11.3
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
Photocure ASA
OSE:PHO
Average EV/EBIT: 1 705.4
61.7
92%
0.7
US
Eli Lilly and Co
NYSE:LLY
47.4
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
16.2
16%
1
CH
Roche Holding AG
SIX:ROG
13.4
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.4
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.4
12%
0.9
CH
Novartis AG
SIX:NOVN
14.4
8%
1.8
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2